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AktGrowth factor-stimulated or cancerous cells require sufﬁcient nutrients to meet the metabolic demands of
cell growth and division. If nutrients are insufﬁcient, metabolic checkpoints are triggered that lead to cell
cycle arrest and the activation of the intrinsic apoptotic cascade through a process dependent on the Bcl-2
family of proteins. Given the connections between metabolism and apoptosis, the notion of targeting
metabolism to induce cell death in cancer cells has recently garnered much attention. However, the signaling
pathways by which metabolic stresses induce apoptosis have not as of yet been fully elucidated. Thus, the
best approach to this promising therapeutic avenue remains unclear. This review will discuss the intricate
links between metabolism, growth, and intrinsic apoptosis and will consider ways in which manipulation of
metabolism might be exploited to promote apoptotic cell death in cancer cells. This article is part of a Special
Issue entitled Mitochondria: the deadly organelle.ondria: the deadly organelle.
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Throughout the lifespan of an individual, the body must contin-
ually balance cell growth and proliferation with cell death to support
proper development and maintain healthy homeostasis of mature
tissues. A central mechanism to control this balance is the dependence
of each cell on survival cues from its microenvironment [1]. Indeed,
the processes of embryogenesis, developmental patterning, and
maintenance of adult tissue require that cells receive proper growth
signals. This social control model ensures that cells that receive the
appropriate cues can survive and proliferate, while cells that fail to
receive sufﬁcient access to these signals, such as excess or damaged
cells, undergo apoptosis, or programmed cell death. These perpetual
processes of cell growth, proliferation, and death are essential for the
optimal function of nearly all tissues and organ systems within the
body, and must be properly coordinated. If cell proliferation lags or
cell death is in excess, degenerative diseases may result; if pro-
liferation exceeds death, neoplastic diseases and cancer may occur.
Interestingly, it has become clear over the past decade that a key
mechanism by which growth signals control cell growth and death is
through regulation of cell metabolism.
In addition to the basal energy needs of resting cells to maintain
osmotic balance and replacement biosynthesis, strong mitogenic or
growth factor stimulation leads to greatly increased metabolic
demands. Speciﬁcally, the doubling of cellular contents requires thatnucleic acid, lipid, and protein synthesis be dramatically increased. To
account for this increased energetic and biosynthetic demand, growth
factors upregulate metabolic pathways essential for proliferation [2]
and, in particular, dramatically increase rates of glucose uptake and
glycolysis. In contrast, when growth factors become limiting, for
instance at the end of an immune response or if excess cells lose
access to appropriate growth factors, cell metabolism, and particularly
glycolysis, decreases. While cells can alter their metabolism to rely
more on mitochondrial oxidation, cells will ultimately undergo
apoptosis in the absence of growth factor signaling. This acute loss
of glucose metabolism is a central element in the initiation of
apoptosis, becausemaintenance of glucose uptake after withdrawal of
growth factors or serum can suppress cell death [3–9]. Thus, cells rely
on growth factors to maintain survival and drive proliferation, in part,
because growth factors regulate cell metabolism to overcome
metabolic checkpoints for proliferation and apoptosis (Fig. 1) [10].
This metabolic check on cell growth and death is most notably
overridden in cancer, where oncogenic kinases can mimic growth
signals, allowing cells self-sufﬁciency to maintain the high rates of
glucosemetabolism required to support cell proliferation. Speciﬁcally,
cancerous cells often rely on the particular metabolic program of
aerobic glycoylsis, ﬁrst noted nearly a century ago by Otto Warburg
[11]. With this metabolic program, cancerous cells demonstrate
markedly increased rates of glucose uptake, glycolysis, and lactate
production, even in the presence of normal oxygen levels, a phe-
nomenon known as ‘the Warburg effect’. It is now clear that, in most
cases, both hypoxia and the very oncogenes that drive cancer cell
proliferation can induce these metabolic changes.
This metabolic phenotype has drawn a great deal of attention in
recent years as a potential new target in cancer therapy. Given
Fig. 1. Growth factor signals and nutrient availability determine cell fate. As growth
factor signals increase the drive for cell proliferation and metabolic demands increase.
Availability of nutrients determines if sufﬁcient resources are present to support cell
survival and growth. If insufﬁcient nutrients are available, cells undergo apoptosis.
These metabolic checkpoints to link nutrients to cell cycle arrest and apoptosis are
critical elements to maintain tissue homeostasis and prevent disease.
Fig. 2. Growth factor or oncogene-stimulated cell metabolism. Through regulation of
signaling pathways such as Akt andMyc growth factors promote glucose and glutamine
uptake for glycolysis and glutaminolysis. Inhibition with these metabolic pathways can
lead to cell death but precise links between speciﬁc metabolic pathways and Bcl-2
family proteins are poorly understood.
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approach could be very fruitful both in cancer as well as in other
instances of inappropriate cell proliferation. Ideally, a metabolic
approach would exploit the dependence of cancer cells on aerobic
glycolysis and metabolic checkpoints to promote cell senescence or
cell death through apoptosis, autophagic cell death or necrosis. The
pathways connecting cell metabolism and apoptosis, in particular,
which form the molecular basis for metabolic checkpoints and would
provide the most direct molecular targets for such an approach, have
only recently begun to emerge. This reviewwill focus on the interplay
between cell metabolism, growth, and the mitochondrial apoptotic
pathway and will discuss how changes in metabolism, such as those
often seen in tumors, might be exploited to induce apoptosis.
2. Metabolic dependencies of proliferating cells
Mitogenic growth factor stimuli can dramatically increase glucose
uptake and aerobic glycolysis to support the metabolic and biosyn-
thetic demands of cell proliferation. This metabolic phenotype is
shared by many highly proliferative cells and appears to be a general
mechanism to allow rapid cell growth. Elevated aerobic glycolysis
generates sufﬁcient amounts of ATP to allow TCA cycle intermediates,
derived from both glucose and glutamine, to exit the mitochondria
and provide carbon backbones for lipid synthesis [2]. Thus, aerobic
glycolysis allows proliferating cells to satisfy their unique biosynthetic
requirements. However, if cell metabolism is not sufﬁcient to meet
these speciﬁc metabolic dependencies, cells arrest and do not divide
and can ultimately undergo apoptosis if nutrients remain limiting.
Several key signaling pathways link proliferation and metabolism
and promote dependence on glucose and glutamine as primary fuel
sources in dividing cells (Fig. 2). Central among them are the
phosphatidylinositol-3-kinase (PI3K)/Akt/mTOR and Myc pathways.
These pathways, which lie downstream of growth factor receptors
and are commonly activated in the context of cancer, stimulate cells to
utilize aerobic glycolysis [12]. In promoting glucose metabolism, Myc
signaling enhances the expression of glucose transporters, as well as
other glycolytic genes [13,14]. In contrast, Akt generally acts post-
transcriptionally to promote the cell surface localization of glucose
transporters [15–17] and enhance hexokinase [18–21] and phospho-
fructokinase [22] activity.Both of these pathways lead to increased glucose metabolism and
enforce a metabolic program with speciﬁc nutrient dependencies. In
addition to aerobic glycolysis, the PI3K/Akt signaling pathway
promotes increased lipid synthesis and suppresses the use of lipids
as fuel, leading to both increased cell growth as well as a dependency
on glucose as a primary nutrient. Akt can stimulate the expression of
lipogenic genes [23] and activity of ATP citrate lyase (ACL), which is
required for the conversion of glucose to lipids [24], and inhibit the
metabolism of other fuels, suppressing autophagy [25] as well as
mitochondrial b-oxidation through decreased expression of carnitine
palmitoyltransferase 1A (CPT1A) [26]. In a parallel set of pathways,
Myc signaling also activates and increases dependency on glutamine
metabolism [27], promoting the expression of glutamine transporters
[28,29] and regulating expression of mitochondrial glutaminase at the
post-transcriptional level [27].
Together, these ﬁndings demonstrate that a key function of the
PI3K/Akt and Myc pathways is to prevent cells from experiencing
nutrient limitation, which can override growth signals and lead to cell
cycle arrest or apoptosis. If nutrients do become limiting, however,
metabolically-sensitive checkpoints are activated to prevent cells
from outstripping their resources. For example, the nutrient-sensitive
kinase AMP-activated protein kinase (AMPK)mediatesmultiplemeta-
bolic checkpoints, activating p53 to induce cell cycle arrest upon
glucose limitation [30] or apoptosis upon glucose withdrawal [31].
Similarly, the transcription factor carbohydrate responsive element
binding protein (ChREBP) appears to be required for the redirection of
glucose into lipid and nucleotide synthesis duringmitogen-stimulated
cell proliferation, and loss of ChREBP induces a p53-dependent cell
cycle arrest [32] (Table 1). Furthermore, the loss of glucosemetabolism
can promote activation of the Bcl-2 family protein Bax to induce
apoptosis, evenwhen excess cytokines are available [3,33–35]. Despite
these observations, however, metabolic checkpoints and metabolic
stress response pathways have, on thewhole, been poorly understood.
3. Mitochondria, the Bcl-2 family, and intrinsic apoptosis
Cell metabolism is tightly linked to the regulation of cell death
through the mitochondria, which serve as a shared platform for
metabolism and apoptosis. Cells that fail to receive sufﬁcient nutrients
ﬁrst reduce metabolism and undergo cell cycle arrest. If cell
Table 1
Metabolic stress and regulation of p53.
Metabolic stress Effect on p53 Downstream
signaling/effects
Growth factor withdrawal p53 activation without
protein stabilization
Puma induction,
apoptosis
Glucose deﬁciency AMPK-dependent S15
phosphorylation and
p53 stabilization
p21 induction,
cell cycle arrest
Glucose deﬁciency AMPK-dependent S46
phosphorylation and
p53 stabilization
Puma induction,
apoptosis
Decreased ChREBP and
loss of glucose-dependent
lipid and nucleotide synthesis
S15 phosphorylation
without p53 stabilization
p21, MDM2, and
TIGAR induction,
cell cycle arrest
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induction of intrinsic, or mitochondrial, apoptosis will occur. The
intrinsic apoptotic pathway is closely tied to the mitochondria, as
seminal work by Wang and colleagues showed that activation of this
pathway was dependent on the mitochondrial protein cytochrome c
[36]. Disruption of the outer mitochondrial membrane during
apoptosis leads to release of cytochrome c from the mitochondrial
intermembrane space into the cytosol, where it can associate with
caspase 9 and Apaf1 to form the apoptosome complex [36,37]. The
exact mechanisms underlying mitochondrial outer membrane per-
meabilization (MOMP) to allow cytochrome c release remain
uncertain (see [38] for an extensive review of MOMP). However, it
is clear that this process requires and is regulated by members of the
Bcl-2 family of proteins.
The Bcl-2 family is divided into three groups, the anti-apoptotic,
multi-domain pro-apoptotic, and BH3-only subfamilies [39]. The
function of Bcl-2 family proteins is regulated largely by protein
interactions between members of the various subgroups. Members of
the anti-apoptotic group, including Bcl-2, Bcl-xL and Mcl-1, directly
bind to and inhibit the action of multi-domain pro-apoptotic proteins.
The multi-domain pro-apoptotic proteins consist of Bax, Bak and Bok,
and the presence of Bax or Bak at the mitochondrial membrane
is required for MOMP and the induction of mitochondrial apoptosis
[40]. Upon activation, Bax and Bak change conformation, homo-
oligomerize to form proteo-lipid pores in the mitochondrial outer
membrane and initiate MOMP and cytochrome c release [41].
The activation of Bax/Bak and induction of MOMP is regulated
by the combined effects of the anti-apoptotic BH3-only proteins. In
unstressed cells, BH3-only proteins are not expressed, or are
sequestered or in zymogen form, while anti-apoptotic Bcl-2 proteins
bind and inhibit Bax and Bak. When cells experience stress, such as
after DNA damage, growth factor withdrawal, or nutrient deprivation,
BH3-only proteins respond by binding and inhibiting anti-apoptotic
proteins to allow the release Bax and Bak, or by directly binding and
activating Bax and Bak [42]. The mechanism by which BH3-only
proteins induce Bax/Bak oligomerization and MOMP remains contro-
versial (see [41–44] for reviews of this topic). However, it is clear that
a cell's fate depends on the recognition of stress by BH3-only proteins
and the resulting changes in the overall balance of pro- and anti-
apoptotic Bcl-2 family members. Therefore, alterations in the levels of
Bcl-2 proteins caused by various cellular processes are critical to the
induction of apoptosis. Interestingly, growing evidence demonstrates
that changes in cellular metabolism regulate checkpoints that control
both pro- and anti-apoptotic Bcl-2 proteins to impact mitochondrial
apoptosis and cell fate.
4. Metabolic stress and the Bcl-2 family
As a central component in cell metabolism and cell death
pathways, mitochondria integrate growth stimuli and nutrient
availability with cell death so that only cells with adequate access tonutrients can survive. In this setting, Bcl-2 family proteins represent
the crucial link between changes in cell metabolism and the control of
apoptosis. Bcl-2 family proteins are regulated by a variety of metabolic
stresses to promote activation of Bax and Bak and cause cell death
(Fig. 3). Inadequate access to growth factor signals or inhibition of
oncogenic kinases leads to decreased glucose uptake and apoptosis
[3,45]. Alternatively, nutrient deﬁciency, such as the glucose or
oxygen starvation that can occur during ischemia or when the blood
supply is limited within developing tissues or tumors, also promotes
activation of pro-apoptotic Bcl-2 family proteins [5,46].4.1. Disruption of growth signals or oncogenic signaling pathways
Growth factor signaling pathways activate the PI3K/Akt pathway
to promote both cell proliferation and cell metabolism. This coor-
dinated control of growth and metabolism allows proliferating cells
to meet energetic and biosynthetic demands. In cancer, activation of
oncogenic kinases, loss of the tumor suppressor PTEN, or activating
mutations in PI3K can all activate the PI3K/Akt pathway to promote
glucose metabolism [47–49]. When these signals are lost or inhibited
and Akt is inactivated, cells internalize nutrient transporters, and
glucose metabolism can decrease dramatically [3,45]. While autop-
hagy can be activated to provide a source in intracellular nutrients
to cushion this sudden metabolic crisis, the acute loss of glucose
metabolism nevertheless can induce metabolic stress and trigger
checkpoints to initiate apoptosis [5,10].
In addition to normal growth factor signals, oncoproteins can
initiate pathways that mimic growth factor signaling. Therefore,
similar to cell death after deprivation of endogenous growth factors,
molecularly targeted therapies that inhibit oncogenic kinases may act
in part through suppression of growth signals that regulate metab-
olism. Indeed, the oncogenic kinase BCR-Abl, which results from the
Philadelphia chromosome translocation and is often expressed in
chronic myelogenous leukemia (CML), has been shown to regulate
Glut1 cell surface trafﬁcking through activation of the PI3K/Akt
signaling pathway [47]. Inhibition of BCR-Abl with the molecularly
targeted therapy imatinib mesylate led to acutely decreased glucose
uptake and cell death [45,50]. It remains uncertain how this metabolic
stress may contribute to imatinib-induced apoptosis, but given
parallels between oncogenic kinase and growth factor signaling,
regulation of cell metabolism may play a critical role in the action of
this and potentially other kinase inhibitors.
In support of this model, BCR-Abl expression has recently been
linked to metabolism through regulation of hypoxia-inducible factor
1-α (HIF-1α), which was found to be upregulated in cancers that
display imatinib resistance caused by BCR-Abl overexpression [51]. In
these cancers, HIF-1a expression drove glucose-dependent ribose
synthesis through activation of transketolase, and treatment with
oxythiamine, which inhibits transketolase, was found to overcome
imatinib resistance and induce cell death. Ultimately, cell death after
imatinib-treatment is dependent on pro-apoptotic Bcl-2 family
members, and both Bim and Bad are thought to be important in this
process [52]. Thus, metabolic links between oncogenic kinases and
Bcl-2 family proteins hold tremendous clinical relevance.
To deﬁne the precise contribution of reduced glucose metabolism
to cell death after growth factor withdrawal or targeted kinase
inhibition, it is necessary to isolate glucosemetabolism from other cell
signaling events that occur downstream of growth factor receptors or
oncogenic kinases. One way that this has been accomplished is by
direct expression of metabolic genes to drive growth factor-
independent cell metabolism. In one system, glucose-6-phosphate
dehydrogenase has been overexpressed to drive glucose ﬂux through
the pentose phosphate pathway [53]. This was sufﬁcient to enhance
cellular transformation and tumorigenesis in mice, although precise
mechanisms were not well deﬁned.
Fig. 3.Model of howmetabolic stress may regulate Bcl-2 family proteins to promote apoptosis. Growth factor deprivation reduces nutrient uptake and anoxia or glucose insufﬁciency
cause direct metabolic stress. In each case, the anti-apoptotic protein Mcl-1 and pro-apoptotic BH3-only proteins are key mediators of metabolic checkpoints to initiate Bax-
mediated cytochrome c release and apoptosis. Speciﬁc details of regulations are uncertain and indicated by ‘?’.
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alone or in combination with hexokinase 1 (HK1) allows cells to
maintain glucose uptake to sustain both glycolysis and the pentose
phosphate pathway even after growth factor withdrawal [3,4].
Consistent with a key role for the acute reduction in glucose uptake
contributing to the death of growth factor-deprived cells, Glut1 and
HK1 expression protected cells from Bax activation and cell death.
Bax, however, was not found to be directly responsive to reduced
glucose metabolism itself. Rather, Bim and Puma were essential for
Bax activation upon growth factor withdrawal. These data demon-
strate that upstream Bcl-2 family proteins can respond to changes in
glucose metabolism in ways that ultimately result in activation of Bax.
Converse experiments, in which nutrients are withdrawn, rather
than artiﬁcially maintained, have also shown that Bcl-2 family
proteins are essential in metabolic stress-induced cell death. Glucose
deprivation can lead to Bax activation [9,33], and, importantly, Bcl-2
[54–56] or Bcl-xL [5,57,58] expression or deﬁciency of Bim or Puma
[5] can protect cells from apoptosis. Thus, a key initiator of cell death
upon loss or inhibition of growth signals is acutely decreased glucose
uptake and metabolism that results in activation of pro-apoptotic Bcl-
2 family proteins.
Mechanisms linking changes in glucosemetabolism to Bcl-2 family
proteins after growth factor withdrawal or inhibition of oncogenic
kinases are now becoming apparent. Both anti- and pro-apoptotic Bcl-
2 familymembers can respond to changes in glucosemetabolism after
cytokine withdrawal to promote Bax activation. Cells withdrawn from
growth factor demonstrate rapid loss of the anti-apoptotic Bcl-2proteinMcl-1 [59], due to phosphorylation of Mcl-1 by GSK-3b [4] and
subsequent degradation by the proteosome [60,61]. This Mcl-1
degradation pathway is initiated by the acute decrease of glucose
metabolism after cytokine withdrawal, as maintenance of glucose
metabolism by expression of Glut1 and HK1 inhibits loss of Mcl-1.
Ultimately, reduced Mcl-1 levels allow pro-apoptotic BH3-only
proteins, such as Noxa, Bim, and Puma, to promote activation of Bax
and Bak [4,5,62]. Of these pro-apoptotic proteins, Noxa does not
appear to be directly regulated by cell metabolism, but rather sets a
threshold for cell death sensitivity [62]. Bim is strongly induced in
response to metabolic stress. Recent work has shown that loss of ATP
in the context of neuronal excitotoxicity leads to AMPK-dependent
induction of Bim [63], suggesting that Bim induction may be
metabolically regulated in certain contexts. However, Bim induction
in response to growth factor or glucose withdrawal does not appear to
be directly dependent on glucose uptake ormetabolism. Rather, Bim is
induced by loss of cell signaling [4] or by initiation of endoplasmic
reticulum (ER) stress [64]. In contrast, Puma induction is highly
sensitive to the loss of cell metabolism, and Puma is unique among
pro-apoptotic Bcl-2 family proteins in that its induction is prevented
in cells ectopically expressing Glut1 and HK1 [5]. These studies have
strongly pointed towards the combined effects of multiple pro-
apoptotic Bcl-2 family proteins, along with reduced levels of Mcl-1, in
the induction of cell death in the context of decreased glucose uptake.
Although multiple Bcl-2 family proteins contribute to cell death
sensitivity, onlyMcl-1 and Puma have been shown to directly mediate
metabolic stress signaling pathways. As such, these two proteins are
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manipulation of glucose metabolism and the induction of apoptosis.
Mcl-1 is well described to have a short half-life [65] and also to be
essential to suppress the pro-apoptotic activity of a variety of BH3-
only proteins to maintain viability of many primary cells [66–69].
Therefore, metabolic control of Mcl-1 degradation is a primary factor
dictating cell survival.
Themechanism of thismetabolic sensitivity ofMcl-1 is not entirely
certain, but growth factor-driven glucose metabolism appears to alter
lipid metabolism to regulate the basal activity of Protein Kinase C
(PKC) family kinases. PKC proteins can, in turn, phosphorylate GSK-3b
to inhibit GSK-3b-mediated phosphorylation and degradation of Mcl-1
[4]. Conversely, acute loss of glucose metabolism after growth factor or
glucose withdrawal may affect lipid proﬁles and lower PKC activity to
decrease inhibitory phosphorylation of GSK-3b and allow Mcl-1
phosphorylation and degradation. PKCs are regulated by lipid binding
[70], and changes in cellular lipid proﬁles in response hyperglycemia
have been shown in a number of different cell types [71–73]. Therefore,
it is possible that cell intrinsic changes in glucosemetabolismmay affect
lipid levels to inﬂuence PKC activity and regulation of GSK-3b. Indeed,
the intracellular localization of PKCm and PKCe is altered in cells
expressing Glut1 and HK1 [4]. This is consistent with a role for PKCs as
sensors of cellular metabolic state, via availability and localization of
speciﬁc lipids, in the regulation of Mcl-1 stability.
Loss of glucose metabolism after cytokine deprivation also
promotes the induction of the BH3-only protein Puma. Puma levels
increase in bone-marrow derived cells withdrawn from IL-3, T
lymphocytes withdrawn from IL-2, and mast cells withdrawn from
a cocktail of cytokine growth factors [5,74,75]. Importantly, upregula-
tion of Puma in this context was suppressed by the maintenance of
glucose metabolism in cells expressing Glut1 and HK1 and was
essential for rapid cell death, as Puma RNAi strongly attenuated
apoptosis of cytokine-deprived cells [5]. Puma is regulated largely at
the transcriptional level [76], and growth factor or glucose depriva-
tion led to sharply increased Puma mRNA. While regulation of Puma
after cytokine withdrawal has been shown to depend partially on
FoxO transcription factors [77], FoxO3a-null cells nevertheless
demonstrate induction of Puma and undergo cell death after cytokine
withdrawal [74,75,77], suggesting that other transcription factors also
play a role as metabolic sensors in the regulation of this Bcl-2 family
protein.
In addition to FoxO3a, the tumor suppressor p53 is a key mediator
of Puma transcriptional induction. Puma was ﬁrst identiﬁed as a p53
target gene [76,78], and p53-null myeloid progenitor cells and
activated T lymphocytes show decreased Puma induction after IL-3
or IL-2 withdrawal, respectively, as compared with wild type cells
[5,75]. Recent work has demonstrated that, in addition to the
canonical DNA damage response pathway, p53 transcriptional activity
increases in the context of cytokine withdrawal [5,75]. The mecha-
nism of this pathway for p53 activation remains unclear. However, the
activation of p53 following cytokine withdrawal was suppressed by
maintenance of glucose metabolism, suggesting a metabolically-
sensitive pathway for p53 activity (Table 1). RNAi knockdown or
genetic knockout of p53 prevented Puma induction, demonstrating
that the metabolic regulation of Puma is likely mediated through a
metabolic checkpoint for p53 activation. A growing number of
connections are being established between p53 and cell metabolism
[30,79,80], and it appears that a fundamental function of p53 may
be to respond to metabolic stress to initiate cell cycle arrest and
apoptosis.
4.2. Nutrient limitation
The high rate of glucose uptake in cancerous cells helps to ensure
that these cells avoid the stress of nutrient limitation as they
continuously grow and divide, but this can occur only when sufﬁcientnutrients are available. In healthy tissues, the blood supply of
nutrients is typically not limiting for basal cell demands. Glucose,
glutamine, and oxygen are available well in excess of the amounts
required for normal cell metabolism. However, if vascularization fails
to meet the needs of growing tissues, such as may occur during
development or in rapidly growing solid tumors, or if blood supply is
limited to an area due to tissue damage, these nutrients can become
restrictive. This is perhaps best appreciated for oxygen limitation, as
poorly vascularized tissues can rapidly become hypoxic [81].
However, glucose diffuses through tissue much less efﬁciently than
oxygen, and it too can become limiting as cells compete to consume
this resource [82].
While low levels of oxygen, or hypoxia, promote an adaptive
transcriptional response through HIF-1 stabilization [83], more severe
oxygen depletion constituting anoxia (oxygen levels ≤0.5%) can
induce translocation of Bax from the cytosol to the mitochondrial
membrane [84] and apoptosis [46]. This cell death is dependent
on activation of pro-apoptotic Bcl-2 family proteins, as expression of
Bcl-xL [46] or deﬁciency of Bax and Bak [85] allow cells to persist even
without oxygen. The mechanism that induces activation of Bax and
Bak in anoxia is not certain, but the inhibition of mitochondrial
oxidative phosphorylation caused by anoxia has been shown to
increase proteasomal degradation of Mcl-1 [85]. The loss of this
important anti-apoptotic protein, then, may greatly sensitize cells to
activation of BH3-only proteins and Bax and Bak.
The roles of BH3-only proteins in anoxia-induced cell death,
however, are less well established, as cells null for Bim, Bid, Puma,
Noxa, and Bad have all been shown to die at rates similar to that of
wild type cells under anoxic conditions [85]. The atypical BH3-only
protein BNIP3 has been shown to be upregulated in response to
anoxia. However, it remains unclear if BNIP3 plays any role in anoxia-
induced cell death, as knockdown of BNIP3 in several cell types failed
to protect from anoxic cell death [86]. In contrast, BNIP3-deﬁciency in
neural precursor cells did attenuate cell death in response to the
hypoxia mimetic desferrioxamine [87]. A key function of BNIP3 may
instead be to facilitate activation of autophagy as an alternate nutrient
stress response pathway and metabolic mechanism [88]. This
metabolic pathway does, however, ultimately rely on mitochondrial
oxidation of lipids and amino acids and, therefore, remains dependent
on some oxygen availability. Thus, it remains unclear which BH3-only
proteins might respond to the metabolic stress of anoxia to promote
cell death or if loss of Mcl-1 alone is sufﬁcient to induce apoptosis.
In contrast to the seemingly limited effects of anoxia on the Bcl-2
family as a whole, limitation of glucose leads to a number of cell
stresses that affect multiple Bcl-2 family proteins. Glut1-deﬁcient
blastocysts have been shown to activate Bax to induce apoptosis
[33,35], and zebraﬁsh lacking Glut1 demonstrate extensive neuronal
apoptosis that can be rescued bymorpholino-mediated knockdown of
Bad [34]. In addition to these in vivo studies, a large amount of work
has addressed how cells respond to metabolic stress by examining in
vitro glucose deprivation. While this approach leads to a multifaceted
cell stress, including metabolic stress, as well as ER stress due to
decreased protein glycosylation and defective protein folding [89,90],
it is nonetheless useful in providing a broad characterization of
how cells respond to these types of injury. Importantly, rescue of
metabolism by addition of cell-permeable metabolites, such as
methyl-pyruvate or alternative metabolic fuels, can demonstrate
that observed effects are due to changes in metabolism rather than to
dysregulated protein folding or other non-metabolic consequences of
insufﬁcient glucose. Using these approaches, it is now clear that
prolonged nutrient deprivation leads to regulation of Bcl-2 family
members to induce mitochondrial apoptosis [91], and this occurs
independently of ER stress pathways.
Similar to cytokine withdrawal, glucose deprivation leads to
increased levels of Bim and Puma [5] and the activation of Bax
[9,33]. Cell death is dependent on these proteins, as expression of Bcl-
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cells from glucose deprivation. However, acute glucose deprivation
differs from cytokine withdrawal in that it induces a rapid decrease in
intracellular ATP levels [92]. This loss of ATP and the resulting increase
in the AMP/ATP ratio can cause the activation of AMP-activated
protein kinase (AMPK) [30,93,94], which has been shown to cause
cell cycle arrest [30] and reduce Mcl-1 protein levels [62,94]
under glucose-limited conditions. Recent work suggests that a block
in Mcl-1 translation, caused by AMPK-dependent [94,95] and
independent [96] inhibition of mTOR, combined with the short half-
life of Mcl-1, causes this loss of Mcl-1 protein that may be critical to
sensitize cells to apoptosis [94].
Metabolic regulation ofMcl-1 levelsmaybeparticularly important in
activated primary T lymphocytes, which primarily utilize glucose and
may exhaust glucose availability in inﬂamed tissues. Noxa can associate
tightly withMcl-1 and is induced during T cell activation.When glucose
becomes limiting, Mcl-1 degradation frees Noxa to promote apoptosis
[62]. Noxa is somewhat unique among the BH3-only family in that it
binds primarily to the anti-apoptotic Bcl-2 proteins A1 and Mcl-1. In
healthy Jurkat T cells, a large percentage of total Noxa was found
associated with Mcl-1 [62]. Interestingly, however, recent work
demonstrated that UV radiation of HeLa cells induced binding between
Noxa and Bcl-xL, whichwas dependent on the loss of Mcl-1, to promote
cell death [97]. Thus, changes in Mcl-1 levels upon glucose withdrawal
may allow liberated Noxa to bind and inhibit Bcl-xL within activated T
lymphocytes, as well, to induce apoptosis.
In addition to affecting the translation of Mcl-1, activation of AMPK
upon glucose limitation can also activate the tumor suppressor p53
(Table 1). Under low glucose concentrations, AMPK causes the phos-
phorylation of p53 on Ser15. While it is not clear if this phosphorylation
is direct, it is associated with the induction of p21 and a p53-dependent
cell cycle arrest [30]. Complete glucose withdrawal also activates p53
through AMPK, and in this context, AMPK leads to p53 phosphorylation
on Ser46 to induce p53-dependent apoptosis [31]. The activation of p53
in the context of glucose withdrawal likely induces cell death through
p53-dependent upregulation of Puma, as shRNA-mediated knockdown
of p53 attenuates Puma induction in hematopoietic cells cultured
without glucose [5]. Furthermore, activated T lymphocytes isolated from
p53 knockout mice demonstrate decreased levels of Puma induction
after glucose withdrawal [5].
This induction of Puma following glucose withdrawal occurs in
response to reduced glucosemetabolism speciﬁcally, rather than as an
indirect effect of other cell stresses caused by glucose limitation. This
has been demonstrated by treatment of cells with a cell-permeable
form of the glycolytic end-product pyruvate, methyl-pyruvate, which
can suppress the increase in Puma levels seen after glucose
withdrawal [5]. This effect was independent of ER stress signaling
pathways, as the addition of methyl-pyruvate did not alleviate the ER
stress caused by glucose withdrawal. Although Puma induction after
glucose deprivation is largely p53-dependent [5], it remains unknown
howmetabolic changes are translated into regulation of Puma protein
levels. In particular, it is not yet clear whether mitochondrial
metabolism suppresses Puma expression entirely through a tran-
scriptional mechanism involving metabolic control of p53 or FoxO
family transcriptional factors, or whether Puma levels are also altered
post-translationally, through changes in protein translation or
turnover. Given the recent work demonstrating post-translational
regulation of Mcl-1 levels after glucose withdrawal, it will be
interesting to discover whether the metabolic regulation of Puma
involves a similar mechanism.
5. Cell death proteins regulate cell metabolism
Given the complex interplay between cellular metabolism and the
induction of apoptosis, it is perhaps not surprising that regulation can
occur in the opposite direction as well, with cell death proteinsinﬂuencing cellular metabolic status. In addition to its role in
promoting cell death, the BH3-only protein Bad is now known to
regulate the activity of glucokinase [98]. Bad can localize to the
mitochondria as part of a large, multi-protein complex with
glucokinase in liver cells [98] and pancreatic b cells [99]. The activity
of glucokinase is dependent on the presence of phosphorylated Bad in
this complex, as genetic deletion of Bad or the presence of a non-
phosphorylatable Bad mutant leads to decreased glucosokinase
activity. Furthermore, Bad knockout mice demonstrate impaired
glucose tolerance [98], glucose sensing, and glucose stimulated
insulin secretion [99]. Thus, the regulation of glucokinase by Bad
seems to extend beyond cellular metabolism to metabolic regulation
at the organismal level. Interestingly, chronic exposure of pancreatic b
cells to high levels of glucose, as might occur with type 2 diabetes, can
promote downregulation of glucokinase expression and increased
apoptosis [100]. It seems possible that the loss of glucokinase
expression may promote apoptosis through release of Bad from its
multi-protein complex, which would allow Bad to neutralize anti-
apoptotic Bcl-2 family members. Thus, it appears that tight regulation
of both metabolic and apoptotic proteins is necessary for proper
pancreatic b cell functioning and glucose homeostasis.
Another protein involved in metabolic stress response pathways
that is traditionally thought of as apoptotic rather than metabolic is
the tumor suppressor p53. As a cell stress-responsive transcription
factor, p53 exerts many of its effects through regulation of a variety of
target genes. Emerging data now demonstrate that p53 has additional
fundamental functions, beyond its roles in genomic repair, cell cycle
progression, and apoptosis, which include the regulation of cellular
metabolism. The p53 target gene synthesis of cytochrome c oxidase 2
(SCO2) is required for assembly of the mitochondrial cytochrome c
oxidase complex and is therefore necessary for mitochondrial
respiration. Cells deﬁcient in p53 signaling have decreased levels of
SCO2 and mitochondrial oxygen consumption and compensatory
increased rates of glycolysis [80]. Additionally, p53 is known to
downregulate expression of the glycolytic enzyme phosphoglycerate
mutase (PGM) [101] and upregulate the expression of TIGAR (TP53-
induced glycolysis and apoptosis regulator) [79]. TIGAR decreases
levels of fructose-2,6-bisphosphate (Fru-2,6-P2). Fru-2,6-P2 allosteri-
cally activates the glycolytic enzyme phosphofructokinase. Thus, p53-
mediated regulation of both PGM and TIGAR serve to lower glycolytic
ﬂux and can instead direct glucose into the pentose phosphate shunt
to help control reactive oxygen species [79].
Interestingly, given the anti-apoptotic effects of increased glycol-
ysis described above, these p53-mediated changes in glucose me-
tabolism seem to fall in line with p53's role as a tumor suppressor. In
combination with its ability to induce expression of BH3-only
proteins, including Bax, Puma, and Noxa, p53 may also promote
apoptosis by decreasing glycolytic rates to relieve the anti-apoptotic
effects of glycolysis. The importance of p53's role in regulating cell
metabolism also becomes apparent when considering that the
majority of cancerous cells demonstrate dysfunctional p53 signaling
that may enhance aerobic glycolysis. This regulation of cell metabo-
lism and links between cell metabolism and apoptosis may thus
reﬂect an additional and generally underappreciated way in which
inactivation or mutation of p53 in cancer cells may enhance cancer
progression.
6. Targeting metabolism in cancer therapy
Given the ﬁndings described above demonstrating intricate links
between cellular metabolism and cell fate, the prospect of targeting
cellular metabolism in cancer seems particularly attractive. The high
frequency with which cancer cells arising from different cell types
adopt a Warburg-like metabolic program suggests that a glycolytic
metabolism is highly beneﬁcial to tumor growth. Therefore, decreas-
ing glycolysis within tumor cells, or driving them back into an
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to reduce cell growth, but also to induce apoptosis. Indeed, the very
signaling pathways that canmediate transformation, such as the PI3K/
Akt pathway, also promote increased glycolysis and may make cancer
cells particularly sensitive to therapies that target glucose metabo-
lism. Akt both promotes aerobic glycolysis and also phosphorylates
CPT1A to inhibit lipid transport into mitochondria [26], thus forcing
cells with activated Akt to rely heavily on glucose as a fuel source.
Similarly, Myc can promote the expression of genes involved in
glutamine metabolism and renders cells highly dependent on this
amino acid as a mitochondrial fuel.
The molecular connections between metabolism and Bcl-2 family
proteins represent themost direct means to exploit cell metabolism in
cancer and potentially develop new, more effective treatment
strategies. However, metabolism occurs within every cell in the
body and is essential to themaintenance of homeostasis. Thus, despite
the tremendously increased rates of glucose uptake and glycolysis
seen in cancerous cells and the large amount of data detailing the links
between metabolism and apoptosis, effective therapies that speciﬁ-
cally target tumor metabolism have remained elusive. It would seem
that two potential strategies for such treatments exist, one that
attempts to directly target the metabolic pathways themselves and
another targeting the proteins that regulate cell metabolism.
Regarding the ﬁrst strategy, it is now apparent that manipulation
of aerobic glycolysis can impact proliferation and survival in cancer
cells. Forcing cells to shift from a glycolytic to a more oxidative
metabolic program may slow tumor growth. Inhibition of lactate
dehydrogenase A, via shRNA-mediated knockdown, increases mito-
chondrial respiration and inhibits cell proliferation in cell culture
experiments and in mouse xenograft models, where resulting
tumors were small and necrotic [102]. Similarly, treatment with
dichloroacetate shifts cells toward oxidative metabolism, through
inhibition of mitochondrial pyruvate dehydrogenase kinase, and
induces cytochrome c release from the mitochondria and apoptosis
in cancer cells [103]. Additionally, inhibition of glucose metabolism
may be an effective means of halting tumor growth, as pharmaco-
logic suppression of PFK activity has been shown to decrease glucose
uptake and impair cancer cell proliferation, both in vitro and in vivo
[104].
Moreover, treatment with the glycolysis inhibitor 2-deoxyglucose
(2-DOG) enhances cisplatin-induced cell death in ovarian cancer cells
[105] and induces apoptosis in prostate cancer cells when used in
combination with the AMPK activator metformin [106]. Perhaps not
surprisingly, combining multiple metabolic stresses, by treating cells
with 2-DOG in the context of hypoxia, has been shown to enhance cell
cycle arrest and cell death above that seen in normoxic cells treated
with 2-DOG [107]. This is thought to reﬂect the fact that hypoxic cells,
unable to produce ATP via oxidative phosphorylation, rely more
heavily on glycolytic metabolism. These ﬁndings imply that the
addition of glycolysis inhibitors to traditional chemotherapeutic
agents may enhance efﬁcacy, by targeting cells within hypoxic
portions of solid tumors that might proliferate more slowly and
thus resist chemotherapies targeting proliferating cells.
Interestingly, inhibition of glucose metabolism may concurrently
protect healthy cells from chemotherapy-induced cell death
[108,109]. It may be that glucose limitation induces a p53-dependent
cell cycle arrest in healthy cells expressing wild type p53 [30],
allowing these cells to arrest and avoid the cytotoxic effects of
chemotherapy. In contrast, p53-null tumor cells may continue to
proliferate and consequently be susceptible to traditional chemother-
apeutic agents. This would also suggest that p53-null cancer cells
might be more sensitive to metabolic manipulation than cancer cells
retaining wild type p53. However, inhibition of glucose metabolism
can also induce p53-dependent apoptosis [31], and cells lacking
functional p53 have been shown to resist caspase activation after
combination treatment with 2-DOG and metformin [106]. Thus, theinduction of apoptosis by metabolic manipulation, and the role of p53
in this process, may be cell type- or context-dependent.
While inhibition of metabolic enzymes and pathways shared
between normal and cancerous tissue is challenging, it is now clear
that cancer cells can express speciﬁc isoforms or mutations of
metabolic enzymes that may be directly targeted to exploit cancer
cell metabolism speciﬁcally. Mutations in two isoforms of isocitrate
dehydrogenase (IDH), IDH1 and IDH2, have been identiﬁed in a large
percentage of certain types of malignant gliomas and in acute mye-
logenous leukemia [110–112]. IDH1, which is found in the cytosol,
and IDH2, located in the mitochondria, exist as homodimers and
catalyze the conversion of isocitrate to a-ketoglutarate in a NADP+-
dependant reaction [113]. Mutant forms of both IDH1 and IDH2
have been shown to decrease the rate of this reaction and to cata-
lyze instead the conversion of a-ketoglutarate to 2-hydroxyglutarate
(2-HG), which accumulates to very high levels within IDH-mutant
cells [114–116]. While the functional effects of this metabolic
alteration remain unknown, targeting of this cancer speciﬁc, mutant
enzyme, or the ‘oncometabolite’ that it produces, represents a
potentially attractive therapeutic strategy.
Also of interest is the altered expression in cancerous cells of the
glycolytic enzyme pyruvate kinase, which converts phosphoenolpyr-
uvate to pyruvate in the rate-limiting ﬁnal step of glycolysis. While
most differentiated adult tissues express the M1 isoform of pyruvate
kinase (PKM1), proliferating cells, including cancer cells, almost
exclusively express the M2 isoform (PKM2) [117]. Expression of
PKM2 promotes aerobic glycolysis over oxidative metabolism, and
this metabolic switch seems to be important for tumor formation, as
forced expression of PKM1 suppresses tumor growth in vivo [117].
Interestingly, within tumor cells, PKM2 is typically found in its less
active, dimeric form [118], and the activity of PKM2 may be further
suppressed by binding to phosphotyrosine peptides [119] found in
abundance in cancer cells. In this scenario, the high rates of glucose
uptake in cancer cells are accompanied by suppression of the ﬁnal
step of glycolysis. The advantage to this seemingly paradoxical
pattern, however, is that glycolytic intermediates upstream of
pyruvate accumulate and can be used as precursors for macromolec-
ular synthesis. In addition, glucose ﬂux through the pentose
phosphate pathway may increase to enhance protection against
reactive oxygen species. These ﬁnding suggest that targeting of PKM2
in cancer may represent a viable strategy.
A second possible method for targeting cancer metabolism to
promote apoptosis is to attack the master regulators of cell me-
tabolism that control the switch to aerobic glycolysis. A number of
molecularly targeted therapies have now been developed against
oncogenic tyrosine kinases, such as Her2/neu, EGFR, and Bcr-Abl. By
inhibiting signaling downstream of these kinases, these therapies
indirectly target the PI3K/Akt pathway, andmany effectively suppress
glucose uptake and metabolism [50,120–122]. Additionally, a number
of PI3K inhibitors are now in phase I and II clinical trials. Whether
these therapies can effectively target such a universally used pathway
without signiﬁcant toxicities remains to be seen. However, preclinical
trials have noted only mild side effects, which predictably included
metabolic disturbances and elevated blood glucose levels [123].
Other potential targets include transcription factors that orches-
trate metabolic changes. Myc inhibition appears to hold potential
based on cell culture assays and animal model experiments [124–
126], although this strategy has not yet been tried in patients. Nuclear
receptors represent another class of transcription factors known to
play a large role in the regulation of cell metabolism. The estrogen
receptor, in particular, has been successfully targeted for the
treatment of breast cancer, demonstrating the drugability of these
proteins. Other nuclear receptors, such as the PPARs [127] and
estrogen related receptors [128,129], regulate multiple aspects of cell
metabolism. However, a role for these proteins as cancer therapeutic
targets remains to be established.
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The metabolic status of a cell is intimately tied to its ability to
successfully grow, proliferate, and survive. If nutrients or metabolic
pathways are not sufﬁcient for these processes, growth factor
stimulation or oncogenic transformation cannot mediate their effects.
Thus, it is not surprising that apoptotic regulatory proteins are closely
associated with cell metabolism and the mitochondria. This system
allows Bcl-2 family proteins to initiate apoptosis in metabolically
stressed cells, rather than allowing cells to survive for prolonged
periods of time through utilization of autophagy as a nutrient source
before ultimately undergoing necrosis [130]. The molecular pathways
that connect metabolism to Bcl-2 family proteins are just beginning to
come into focus, but given the fundamental role of cell metabolism in
regulating cell fate, these mechanisms will be of great interest in a
variety circumstances. In particular, strategies to kill cancer cells by
exploiting metabolic addiction may beneﬁt from an increased
understanding of which metabolic stress pathways are most closely
linked to the induction of apoptosis by the Bcl-2 family.
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